Search results
Earnings call: Vir Biotechnology reports Q1 2024 financials, pipeline progress By Investing.com
Investing.com· 13 hours agoNoteworthy developments include promising preliminary data from its hepatitis B program and the...
U.S. Lags Behind Other Countries in Hepatitis-C Treatment
New York Times· 6 days agoIn the 10 years since the drugmaker Gilead debuted a revolutionary treatment for hepatitis C, a wave...
Arbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 12 hours agoArbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call Transcript May 2, 2024 Arbutus...
Arbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
GuruFocus.com via Yahoo Finance· 20 hours agoData will be shared as it becomes available from the ongoing...Phase 2 study, following the completion of the current Phase 1 study which includes multiple doses in patients with chronic < ...
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Fina
Guru Focus· 2 days agoRevenue: Reported at $1.5 million for Q1 2024, a significant decrease from $6.7 million in Q1 2023, falling short of the estimated $2.15 million.Net Loss: Reco
Change Eligibility Rules for More Diverse Clinical Trials?
Medscape· 22 hours agoExpanding eligibility criteria is a strategy for improving the inclusion of traditionally...
Vir Biotechnology (VIR) Scheduled to Post Earnings on Thursday
ETF DAILY NEWS· 3 days agoVir Biotechnology (NASDAQ:VIR – Get Free Report) is scheduled to be releasing its earnings data after the market closes on Thursday, May 2nd. Analysts expect Vir Biotechnology to post earnings ...